US FDA advisers vote for adapalene OTC switch

19 April 2016 - Deborah Wilkes

Archived

Advisers to the US Food and Drug Administration (FDA) have voted in favour of Galderma's application to switch adapalene – the active ingredient of its acne medicine Differin – from prescription to OTC status.

Click tags below for more information on topics:

Nestlé Galderma FDA CHPA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: